We welcome your feedback and / or questions related to the
educational content provided through GuidelineStat™ Bipolar Disorder.
Release date:
September 1, 2009
Expiration date:
September 1, 2010
Click here to view Technical Requirements
Accreditation
This learning activity has been designated for 1.75 AMA PRA Category 1 Credits™.
Physicians should only claim credits commensurate with the extent of their participation in this activity.
Target Audience
This learning activity is intended for a broad audience of healthcare practitioners, including primary care physicians, family physicians, emergency medicine physicians, psychiatrists, psychologists, nurse practitioners, and physician assistants or other healthcare professionals with an interest in treating patients with Bipolar Disorder.
Learning Objectives
As a result of participating and interacting in this activity, participants will be better able to:
- Clarify the current standard treatment algorithm for a patient with previously well controlled bipolar disorder who becomes depressed on medication and discuss potential causes for breakthrough
- Evaluate available psychopharmacologic therapy options which would be appropriate in various bipolar disease scenarios along the continuum of care
- Describe the potential side effects of mood enhancing agents in individuals diagnosed with bipolar disorder and review options for managing these events
Author
Boadie W. Dunlop, MD
Director
Mood and Anxiety Disorders Program
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia
Dr Boadie Dunlop is paid by Imedex, LLC to provide this information.
The opinions expressed are those of Dr Boadie Dunlop and do not
necessarily reflect the views of Emory or EmoryHealthcare.
Dr Boadie Dunlop’s participation in this activity does not
constitute or imply endorsement by Emory or EmoryHealthcare.
Medical Writers
Don Harting, MA, ELS
Imedex, LLC
Disclosure of Financial Interests
As an accredited provider of continuing medical education, Imedex, LLC is required to ask authors to disclose any real or apparent conflict of interest they may have as related to the content of their chapter(s). The existence of commercial or financial interests of speakers related to the subject matter of their chapter(s) should not be construed as implying bias or decreasing the value of their chapter(s). However, the disclosure should help participants form their own judgments.
All authors were independently selected by the organizing committee.
Those authors who disclosed affiliations or financial interests with the
commercial organizations involved with products, to which they may refer are listed below.
- grant research
- consultant
- speaker's bureau
- stock shareholder
- other support
Dr Boadie W. Dunlop
Supporters of this activity:
AstraZeneca1
Other affiliations:
Digitas Health2
GlaxoSmithKline Inc.1
Takeda Pharmaceutical Company Ltd.1
Wyeth Pharmaceuticals1
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA, owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.
Bradley Bongiovanni, ND, Becky Lynch, RN, Emily Geiger, and Don Harting, MA, ELS own stock options for AmerisourceBergen.
Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.
Disclosure of Unapproved Uses and Investigational Drugs
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
Statement of Commercial Support
The following company has provided an unrestricted educational grant in support of this activity: AstraZeneca
(*Please check this box to proceed - required)
|